TP53 and cancer: A closer analysis of the associations between different TP53 subtypes and lymph node metastases showed that the group of TP53 unaltered cancer patients displayed a much smaller fraction of N1+ tumors (~36%) than either the TP53 missense mutation (~48%) or gene deletion group (~44%) (Fig. S1).